Johnson & Johnson shares advanced to near their 52-week peak in recent trading, outperforming a broader market pullback driven by escalating Middle East tensions and oil price surges, as investors sought refuge in the healthcare giant's stable earnings, robust dividend and diversified portfolio.

The new US FDA warning label is a further blow for Johnson & Johnson, which was granted an emergency use authorization for its shot in February 2021 but has played a minor role in America's coronavirus immunization campaign
Johnson & Johnson

The company's stock (NYSE: JNJ) closed at $248.43 on Feb. 27, 2026, up $4.96 or 2.04% from the previous session, on elevated volume of over 16.4 million shares — about 70% above average. In early March 3 trading, shares hovered around $249.24, up modestly in a session where futures indicated pressure from geopolitical risks. The rally pushed JNJ within striking distance of its intraday high of $248.94 from late February, marking a 52-week range from $141.50 to nearly $252. Year-to-date gains exceed 10%, with the stock up about 38% over the past six months despite ongoing talc litigation headwinds.

Johnson & Johnson's resilience stems from its January 2026 earnings report for the fourth quarter and full year 2025. The company posted strong results, with full-year sales growth supporting an upbeat 2026 outlook. Q4 revenue reached approximately $24.28 billion, while adjusted EPS came in at levels that beat some expectations despite a slight miss in certain views ($2.46 vs. consensus near $2.47). Innovative Medicine (pharmaceuticals) and MedTech segments drove performance, with key products like Darzalex and Tremfya showing robust sales.

For 2026, J&J guided reported sales to $99.5 billion to $100.5 billion (midpoint $100.5 billion, up about 6.7%), and adjusted EPS of $11.43 to $11.63 (midpoint $11.53, up 6.9%). The forecast exceeded Wall Street estimates even after factoring in impacts from drug pricing agreements with the Trump administration and potential tariffs on medical devices, estimated at hundreds of millions. Analysts praised the guidance as conservative yet achievable, highlighting oncology pipeline strength and biosimilar competition offsets.

The company maintains a market capitalization approaching $600 billion, with a forward P/E ratio around 22-23 — viewed as attractive for a blue-chip healthcare name. The quarterly dividend of $1.30 per share (annualized $5.20, yield about 2.09%) remains a draw for income investors. The ex-dividend date was Feb. 24, 2026, with payment on March 10.

Recent pipeline advancements bolster confidence. In late February, J&J reported promising early Phase 1b results for pasritamig (a bispecific T-cell engager) combined with docetaxel in advanced prostate cancer, showing deep PSA reductions and manageable safety. On Feb. 24, the company submitted a supplemental Biologics License Application to the FDA for IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). Upcoming presentations include the Barclays Global Healthcare Conference on March 10 and TD Cowen on March 3.

Talc litigation continues to cast a shadow, though the stock's performance suggests investors are pricing in manageable risk. As of early 2026, the multidistrict litigation includes over 67,000 plaintiffs alleging ovarian cancer or mesothelioma from talc products. Recent verdicts include a $250,000 award in a Philadelphia case in February for a deceased user's family, and larger prior awards like $1.5 billion in a 2025 mesothelioma trial (under appeal). J&J insists its products are safe and asbestos-free, pursuing appeals and settlement discussions. No global resolution has emerged post-bankruptcy attempts.

Analysts maintain a consensus "Moderate Buy" rating, with average price targets around $233 (some as high as $262), implying modest upside or stability from current levels. Firms like Morgan Stanley upgraded to Buy with a $262 target in January, citing improving 2026 prospects.

In a market facing geopolitical uncertainty — with oil surging on Iran-related developments — JNJ's defensive characteristics shine. Healthcare stocks often hold up during risk-off periods, and J&J's low beta, consistent cash flow and innovation in high-growth areas like oncology position it well.

The company continues executing its post-Kenvue separation strategy, focusing on Innovative Medicine and MedTech for sustained growth. With next earnings expected around April 14, 2026, investors will watch for updates on pipeline momentum, litigation developments and macro impacts.

Johnson & Johnson's blend of stability, yield and growth potential keeps it a core holding for many portfolios amid broader volatility.